The QualityStocks Daily Newsletter team will be off November 22nd & 23rd to enjoy time with family & friends, but we want to wish all of you a Happy Thanksgiving and we will see you again on Monday, November 26th!

The QualityStocks Daily Tuesday, November 20th, 2018

Today's Top 3 StockMarketWatch

BUYINS.NET (ANY) +144.81%

Wolf of Penny Stocks (ADVT) +54.90%

StreetInsider (ORPN) +30.25%

The QualityStocks Daily Stock List

Know Labs, Inc. (KNWN)

Amigo Bulls, Business Wire, 4-Traders, YCharts, Open Insider, Marketbeat, last10k, Stockwatch, VentureLine, MarketWatch, Simply Wall St, Stockopedia, Investors Hangout, TradingView, High Rising Stocks, Dividend Investor, OTC Markets, Spotlight Growth, Insider Tracking, Stockhouse, Insider Monkey, InvestorsHub, Street Insider, and Wallet Investor reported earlier on Know Labs, Inc. (KNWN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Know Labs, Inc. is developing a new technology platform that measures blood glucose non-invasively. The OTCQB-listed Company invented a pioneering technology called Bio-RFID that will provide information to consumers about their health and wellness. Additionally, Know Labs utilizes its proprietary ChromaID technology to identify unique molecular signatures in materials. The Company previously went by the name Visualant, Incorporated. It changed its name to Know Labs, Inc. in May 2018. Know Labs has its corporate headquarters in Seattle, Washington.

The Company develops technology platforms that harness light and radio waves to uncover distinct insights about the world. Its technology directs electromagnetic energy through a substance or material to capture a unique molecular signature. Know Labs refers to these signatures as ChromaID™ and Bio-RFID™. ChromaID and Bio- RFID are used to identify, detect, or diagnose substance markers or biomarkers that may be invisible to the human eye.

ChromaID and Bio-RFID scanner modules can be integrated into an array of mobile or bench-top form factors. This patented and patent pending, award-winning technology makes it possible to effectively conduct analyses that could only previously be performed by invasive and/or large and expensive lab-based tests.

Know Labs announced in August 2018 its UBAND™ real time wearable calorie counter wrist band. The Calorie Counter UBAND is built upon the Company’s recent invention that detects blood glucose non-invasively. At present, Know Labs has 12 issued patents with 20 pending, covering its specialty.

Last month, Know Labs released a video highlighting its product pathway and platform. In the video, Chief Executive Officer, Mr. Phil Bosua, discusses the Company’s Bio-RFID™ technological breakthrough and the plans for bringing the technology to market.

The transcript of Mr. Bosua’s narrative in the video states in part, “We originally set out to detect blood glucose and in turn, created a platform. We’ve begun initial research to measure all types of substances in the blood and interstitial fluid. Biomarkers like cortisol for stress levels, as well as continuous measurement of the luteinizing hormone, which would indicate ovulation within the next 4 hours – ideal for those wanting to get pregnant. We’re now ahead of schedule and look forward to creating the future of non-invasive health measurements.”

Know Labs, Inc. (KNWN), closed Tuesday's trading session at $1.8475, down 6.69%, on 9,840 volume with 16 trades. The average volume for the last 3 months is 11,544 and the stock's 52-week low/high is $0.205/$5.75.

chart

Khiron Life Sciences Corp. (KHRNF)

Investors Hangout, TradingView, Wallmine, OTC Markets, Wallet Investor, Investing News, Capital Network, InvestorsHub, Pot Network, Penny Stock Hub, Stockwatch, Stockhouse, Midas Letter, Barchart, Morningstar, Proactive Investors, MarketWatch, Market Screener, and GuruFocus reported on Khiron Life Sciences Corp. (KHRNF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Khiron Life Sciences Corp. is a Canadian integrated medical cannabis enterprise. It has its core operations in Colombia. Khiron is fully licensed in Colombia for the cultivation, production, domestic distribution, as well as international export of tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. Khiron Life Sciences has its head office in Toronto, Ontario and an office in Bogota, Colombia. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Khiron combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to grow prescription and brand loyalty to address priority medical conditions. These conditions include chronic pain, epilepsy, depression and anxiety in the Latin American market. The Company is creating research partnerships with some of Colombia’s top medical associations – the Colombian Association of Neurology being one of them.

Khiron also has the advice of the best laboratories from Israel and Canada in genetics and, production and clinical data of medical cannabis. Concerning the cultivation process and product development, the Company has developed a temperature, humidity, and air circulation control system, which ensures that the plant grows in a controlled natural environment. Khiron’s cultivation is hydroponic.

Khiron Life Sciences announced in August of this year that it notified the Colombian Ministry of Justice that it expanded its cultivation area to 17.5 hectares of prime agricultural land near Ibague, Colombia . The cultivation site has an ideal climate profile, and an abundance of water, power, and skilled labor to scale cultivation and production. The cultivation area is in a highly secure region of Colombia.

Last month, Khiron Life Sciences announced that it signed the definitive agreement for the acquisition of the Latin American Institute of Neurology and the Nervous System (ILANS) earlier announced on August 7, 2018 . ILANS is one of the most respected, fastest growing, and largest neurological clinics in Colombia. It becomes a foundation of the Khiron Clinics business unit in Latin America.

Earlier this month, Khiron Life Sciences announced that it extended an agreement with Farmalisto, the region’s foremost digital drugstore, to market and distribute the Company's Kuida®  CBD cosmeceutical brand to a population of greater than 120 million consumers in Mexico. This is subject to approvals from the Federal Commission for the Protection of Health Risks (COFEPRIS).

Yesterday, Khiron Life Sciences announced that it received additional quotas from the Colombian Technical Quotas Group (TQG), to cultivate 5,040 psychoactive cannabis plants for the purposes of completing the Colombian Agricultural Institute (ICA) agronomic evaluation tests. This represents an important milestone towards the Company's stated timeline to bring medical cannabis options to market in Colombia.

Khiron Life Sciences Corp. (KHRNF), closed Tuesday's trading session at $1.05, down 10.23%, on 271,669 volume with 230 trades. The average volume for the last 3 months is 268,610 and the stock's 52-week low/high is $0.664/$1.59.

chart

Beyond Commerce, Inc. (BYOC)

Zacks, Penny Stock Tweets, Tip Ranks, 4-Traders, GuruFocus, Stockopedia, OTC.Watch, TradingView, Morningstar, Stockhouse, InvestorsHub, YCharts, Street Insider, Market Screener, Wallet Investor, Simply Wall St, Financial Content, MarketWatch, Investors Hangout, Barchart, The Street, Insider Financial, Stockinvest, and OTC Markets reported on Beyond Commerce, Inc. (BYOC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Beyond Commerce, Inc. is a planned provider of B2B (Business to Business) internet marketing analytics, technologies, and related services. Its planned goal is to develop, acquire, and deploy disruptive strategic software technology, which will build on organic growth potential. In addition, its planned goal is to exploit cross-selling opportunities. Beyond Commerce has its corporate headquarters in Las Vegas, Nevada. The Company lists on the OTC Markets Group’s OTCQB.

Beyond Commerce operates as a holding enterprise that concentrates on “big data” companies in the international B2B Internet Marketing Analytics/Technology and Services space. The Company plans to provide a cohesive digital product and services platform. This is to provide clients with a single point of contact for their big data, marketing and related sales initiatives. Beyond Commerce’s emphasis is to develop, acquire, as well as deploy disruptive strategic software technology and market-changing business models via acquisition or organic growth.

This past August, Beyond Commerce announced that it was added to the LD Micro Index effective August 1, 2018. Mr. George Pursglove, Beyond Commerce Chairman and Chief Executive Officer, stated in August, "This is an exciting time for us as we continue to execute on business milestones which are translating into additional exposure in the capital markets and building on our goals for corporate transparency and credibility with stakeholders.

Moreover, in October, Beyond Commerce announced that it filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC). The Form S-1 filing was made in connection with the Company’s intention to up-list it's securities to a national exchange. The Form S-1 includes the consolidated audited financial statements for the years ended December 31, 2017 and 2016. Also included are the condensed consolidated reviewed financial statements for the three and six month periods ended March 31, and June 30, 2018 and 2017.

Beyond Commerce, Inc. (BYOC), closed Tuesday's trading session at $0.06985, down 11.47%, on 789,916 volume with 67 trades. The average volume for the last 3 months is 722,736 and the stock's 52-week low/high is $0.00255/$0.1599.

chart

Grom Social Enterprises, Inc. (GRMM)

InvestorsHub, PinkSheets, and Stockhouse reported on Grom Social Enterprises, Inc. (GRMM), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Grom Social Enterprises, Inc. wholly owns four separate subsidiaries. This includes Grom Social, which is a safe social media platform for children between the ages of five and 16. Formed in 2012, Grom Social has attracted children and parents with the promise of a safe and secure environment where their kids can be entertained and can interact with their peers while learning proper digital citizenship. OTCQB-listed, Grom Social Enterprises is based in Boca Raton, Florida.

With Grom Social, kids can create a profile; make friends, chat, as well as share content. Grom is a social community with a wide assortment of original content and engaging features. These include exclusive Grom TV videos, fun Grom games, interesting photos, and thought provoking Fan Pages. These range in topics from good digital citizenship and internet safety, to entertainment, sports, creative DIY (Do-It-Yourself) projects and more.

Inappropriate content or behavior (photos, language, bullying, and more) on Grom Social is identified by digital filters and the Company’s cast of Grom Helpers. Grom Helpers are real people. They monitor the website 24 hours a day, 7 days a week, 365 days a year.

Grom Social has its Parent Portal. This is a tool available to parents and guardians. It allows them to monitor and control all of their child’s activity on Grom Social. Parents can set privacy settings; examine chat histories; and review and control who their child is friends with.

Grom Social Enterprises also owns and operates Top Draw Animation, Inc. This is an award-winning animation enterprise. Top Draw Animation produces animated content for Grom Social and other high-profile media properties. These include Tom and Jerry, My Little Pony, and Disney Animation's Penn Zero: Part-Time Hero.

Furthermore, the Company’s Grom Nutritional Services is in the process of creating a line of healthy nutritional supplements for children. Of note is that Grom Social Enterprises has one of the longest session duration times in the social media industry. Users spend an average of 52 minutes on the site each visit.

Grom Social Enterprises’ subsidiary, Grom Educational Services (GES), opened a new 1,400 square foot office in Norcross, Georgia on January 1, 2018. This is to house the Company’s NetSpective Webfilter division. GES, doing business as (d/b/a) NetSpective Webfilter, provides proprietary Internet filtering software, to greater than 3,700 schools and more than 2 million children. GES generates revenue by way of a subscription model.

This past January, Grom Social Enterprises announced that it acquired the assets of New Jersey-based Fyoosion, LLC. Included in the assets acquired is a proprietary software, which uses a digital automation marketing platform for businesses of all kinds. It enables companies to efficiently produce sales leads and improve customer retention. Grom Social Enterprises’ intention is to use this marketing software with all of its existing businesses and to create new opportunities outside its present range of business.

Grom Social Enterprises, Inc. (GRMM), closed Tuesday's trading session at $0.30, up 3.45%, on 6,700 volume with 6 trades. The average volume for the last 3 months is 18,663 and the stock's 52-week low/high is $0.10/$0.96.

chart

DroneGuarder, Inc. (DRNG)

OTC Markets, Barchart, StreetRegister.com, Insider Financial, InvestorsHub, 4-Traders, and Emerging Growth.com reported on DroneGuarder, Inc. (DRNG), and today we report on the Company, here at the QualityStocks Daily Newsletter.

DroneGuarder, Inc. centers on commercializing a drone enhanced home security system as a turnkey solution. The design of its DroneGuarder Mobile App is to let users have peace of mind within arms length, whether they are in their home or not. Established in San Francisco in 2017, DroneGuarder has its head office in London, England.

The Company’s solution is app-based. It includes a drone, infrared camera, and an Android mobile app component. Upon an alarm being triggered, the DroneGuarder™ will immediately take off from a wireless charging pad.

The DroneGuarder™ assists in protecting against intruders. Upon an intruder being detected on the sensor net, one can have the drone fly to the event location. Once there, one can use the built-in microphone to issue a harsh warning to scare away intruders. If that fails, the high-quality HD film captured of the intruder can be uploaded to the cloud and forwarded to law enforcement agencies.

A variety of DJI drones is available and compatible with the DroneGuarder system. The design of the drones is to respond to commands from a user’s smart phone, and its native remote. This enables one to give it basic orders from anywhere.

DroneGuarder uses Swellpro as its drone supplier. DroneGuarder’s intention is to work jointly to embed its scanning AI image recognition technology into Swellpro’s SD5 drone platform. This will enable the DG Rescue to autonomously grid search for victims in a search area and alert the rescue crews through GPS location and streaming video where the victims are. DroneGuarder will be jointly developing DG Intruder with Swellpro using all the same technology, however it will be app based.

This past January, DroneGuarder announced the launch of its DG App on Google Play. The Company is enhancing the functionality for login and flight control including autonomously and controlled security sweeps. DroneGuarder secured new funding, which enables the Company to fund DG Rescue and DG Intruder product developments through to commercial release.

DroneGuarder believes that once both of its products are launched it will sell 5,000 to 10,000 drone units in the first year. The Company has its channels to market already in place, using Swellpro’s reseller network. Swellpro in 2017 sold roughly 6,000 drones.

DroneGuarder, Inc. (DRNG), closed Tuesday's trading session at $0.0067, up 11.67%, on 162,500 volume with 5 trades. The average volume for the last 3 months is 329,978 and the stock's 52-week low/high is $0.0049/$0.187.

chart

Advanced BioMedical Technologies, Inc. (ABMT)

Zacks, Stockrow, and 4-Traders reported on Advanced BioMedical Technologies, Inc. (ABMT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Advanced BioMedical Technologies, Inc. manufactures and distributes advanced impedance controlled micro-current instruments. The Company has treated more than 15,000 patients during the past 28 years. It is a leader in education, research, training, and instrument sales and works with doctors and clinicians throughout the U.S. This includes those in Minnesota, the majority of which have an affiliation with the University of Minnesota. Advanced BioMedical Technologies is based in Eagan, Minnesota.

The Company is the oldest distributor of the Electro-Acuscope and Electro-Myopulse. Advanced BioMedical has a 6,000-square foot office complex, with 3,000 square feet dedicated as a patient care treatment center.

The Electro-Acuscope and Electro-Myopulse instruments feature the most sophisticated computerized, feedback-controlled, energy delivery, micro-current technology available today. Acuscope products include the Electro-Acuscope 85P (Portable); the Electro-Acuscope 80L; and the Neuroscope 230B. Myopulse products include the Electro-Myopulse 75L (Base Model) and the Electro-Myopulse 75F (used in Fermi Lab Study).

The Electro-Myopulse measures the Bio-Impedance of the muscle tissue between the two electrodes. Similarly, this is how the current amplitude and voltage output is adjusted and controlled. The Myopulse uses a sine wave. This sine wave imitates the wave produced when a muscle first contracts.

The Electro-Acuscope monitors nerve conduction between two electrodes. This is how the current amplitude and voltage output is adjusted and controlled. The Acuscope uses a complex waveform. This waveform imitates a nerve impulse.

The Neuroscope 230B (Home Care Unit) is for the personal treatment of sleep, anxiety, and pain issues. The product is a personal treatment device for the person on the go. Moreover, it is as an adjunct to Acuscope and Myopulse (impedance controlled microcurrent) therapy where extended rehabilitation therapy require more treatments at home.

The design of the Electro-Acuscope 85P (Portable) instrument is for the traveling clinician or patient (with prescription). This instrument is built into a haliburtor case for safe and easy portability.

Furthermore, Advanced BioMedical Technologies has its La Fleur products. These include the Electro-Myopulse 75LN Premium Instrument (Myopulse, Facial and Esthetics), which was developed exclusively by the Company. In addition, the Company carries a line of Accessories.

Recently, Advanced Biomedical Technologies announced that the State Intellectual Property Office of The People’s Republic of China (SIPO) issued the Company a new patent titled “Bone Fracture Plate Made of High Polymer Materials”.

Its subsidiary Shenzhen Changhua Biomedical Engineering Company Limited is entitled for the new patent (ZL 2014 1 0647464.1), which strengthens the Company's position in manufacturing process and related controls using its innovative polyamide materials (PA).

Advanced BioMedical Technologies, Inc. (ABMT), closed Tuesday's trading session at $0.20, up 17.65%, on 1,077 volume with 1 trade. The average volume for the last 3 months is 453 and the stock's 52-week low/high is $0.125/$2.00.

chart

Freedom Holding Corp. (FRHC)

Stockflare, The Stock Market Watch, OTC Markets, Marketbeat, Stockopedia, Stockwatch, Investors Hangout, Barchart, Wallet Investor, Simply Wall St, Stockhouse, Last10K, 4-Traders, InvestorsHub, MarketWatch, and Insider Monkey reported on Freedom Holding Corp. (FRHC), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Freedom Holding Corp. conducts retail financial brokerage, investment counseling, securities trading, investment banking and underwriting services via its subsidiaries under the name of Freedom Finance in the Commonwealth of Independent States (CIS). A financial services holding company, Freedom Holding is based in Almaty, Kazakhstan. The Company has supporting administrative office locations in the United States, Russia, and Cyprus. Freedom Holding is a professional participant on the Kazakhstan Stock Exchange (KASE), the Moscow Exchange (MOEX), the Saint-Petersburg Exchange (SPB), the Ukrainian Exchange, and the Republican Stock Exchange of Tashkent (UZSE).

Freedom Holding announced in April 2018 the opening of its first branch office of Freedom Finance in Tashkent, Uzbekistan. This office is in the city's International Business Center. Freedom Holding announced in May 2018 that its subsidiary Freedom Finance JSC successfully completed the acquisition of Asyl-Invest JSC. This acquisition joins the two largest retail brokerage firms in Kazakhstan serving more than 50,000 client accounts. Freedom Finance JSC is the largest retail brokerage firm in the Republic of Kazakhstan.

This acquisition provides thousands of new investors with access to Freedom Finance's TRADERNET trading platform. This acquisition also provides investors with access to fourteen branch offices across Kazakhstan and over 223 employees working as customer consultants, securities analysts and traders in Kazakhstan.

Freedom Holding announced this past June that its subsidiary LLC IC Freedom Finance (Moscow, Russia based) completed the acquisition of Nettrader Brokerage Company.  LLC IC Freedom Finance is now, in terms of the number of its registered clients, the eighth largest retail securities broker in Russia. This is according to data published by the Moscow Exchange.

In September of this year, Freedom Holding held its annual meeting of shareholders in Moscow, Russia. In his annual meeting address to the shareholders Timur Turlov (Chairman of the Board of Directors and Chief Executive Officer) said, "During the week before our meeting of shareholders our retail brokerage division reached a major milestone in client accounts. We now exceed a total of 100,000 client accounts. That is tremendous growth from 2012 when we serviced only 2,000 client accounts… "

Last month, Freedom Holding announced that its subsidiary Investment Company Freedom Finance collaborated with London-based, FinEx Capital to launch trading of FXKZ, which is the world's first ETF to track the index of the Kazakhstan Stock Exchange (KASE). FXKZ is domiciled in Ireland. Bank of New York Mellon is the ETF service provider. FXKZ is traded on the Moscow Stock Exchange (MOEX). It is priced in Russian Rubles.

Freedom Holding Corp. (FRHC), closed Tuesday's trading session at $8.19, down 3.65%, on 28,258 volume with 62 trades. The average volume for the last 3 months is 21,906 and the stock's 52-week low/high is $4.25/$9.21.

chart

Future Farm Technologies, Inc. (FFRMF)

InvestorsHub, MarketWatch, Stockhouse, Morningstar, Barchart, Weed Newswire, OTC Markets, MarketNewsUpdates.com, and 4-Traders reported on Future Farm Technologies, Inc. (FFRMF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Future Farm Technologies, Inc.’s business model includes developing and acquiring technologies, which will position the Company as a leader in the development of Controlled Environment Agriculture (CEA) for the worldwide production of different kinds of plants, with an emphasis on cannabis. The Company has projects throughout North America. This includes California, Florida, and Maryland.

Established in 1984, Future Farm Technologies is headquartered in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQB. It previously went by the name Arcturus Growthstar Technologies, Inc. It changed its name to Future Farm Technologies, Inc. in February of 2017. The Company has its U.S. office in Dedham, MA.

Future Farm Technologies is quickly becoming a foremost indoor plant growth technology company specializing in LED lighting and vertical farming solutions. The Company provides scalable, indoor CEA systems that use minimal land, water and energy regardless of climate, location or time of year. These systems are customized to grow an abundance of crops close to consumers.

In addition, Future Farm Technologies holds an exclusive global license to use a patented vertical farming technology that, when compared to traditional plant production methods, produces yields up to 10 times greater per square foot of land. Moreover, the Company employs a leading cannabis oil extraction technology that enables it to process 20lbs/hour of cannabis plant to yield roughly 908 grams/hour of oil.

Furthermore, Future Farm Technologies designs and distributes LED lighting solutions using the COB and MCOB technology. The Company has advanced e-commerce sites that it owns and operates. Its LEDCanada.com caters to B2B customers. It is a supplier of the newest and highest demand LED solutions. Its COBGrowlights.com caters to small and large agriculture green houses and controlled cultivation centers.

Future Farm Technologies recently acquired the exclusive right to use a patented, augmented reality (AR) technology in the cannabis industry. It will work with its partner to merge AR and ad-tech with the cannabis industry via the CannaCube Live™ platform.

Recently, Future Farm Technologies announced that it entered into a definitive agreement with New England CCS to acquire a 51 percent stake in FlipCoin, a new cryptocurrency application and Point of Sale (POS) platform for cannabis dispensaries. The FlipCoin application will permit dispensaries to accept Bitcoin, Ethereum, Bitcoin Cash, or Litecoin as payment.

Last week, Future Farm Technologies announced that it signed a building lease for its Industrial Hemp CBD Oil production and propagation in Maine. The Company announced that it entered into a lease agreement for an initial 12,960 sq. ft. of space in a 60,000 sq. ft. building, with an option to expand and/or purchase the building.

Additionally, last week, Future Farm Technologies announced that it closed on the purchase of a 15,000-sq. ft. building in Providence, Rhode Island. This building is in an M-1 zone that legally allows the cultivation of cannabis by right. Future Farm Technologies’ intention is to lease this property to a local, licensed cultivator who will use the property as a licensed medical marijuana cultivation space, providing wholesale cannabis to Rhode Island's state-sanctioned dispensaries.

Future Farm Technologies, Inc. (FFRMF), closed Tuesday's trading session at $0.244, up 13.49%, on 629,800 volume with 205 trades. The average volume for the last 3 months is 612,939 and the stock's 52-week low/high is $0.129/$1.66.

chart

Workhorse Group, Inc. (WKHS)

CapitalCube, GuruFocus, Simply Wall St, StreetInsider, Stockhouse, Equity Clock, Investing, Last10K, Zacks, Investopedia, Stocktwits, MarketWatch, InvestorsHub, 4-Traders, Morningstar, The Street, and Business Insider reported earlier on Workhorse Group, Inc. (WKHS), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Workhorse Group, Inc. is a technology company focused on providing sustainable and cost-effective electric mobility solutions to the commercial electric transportation sector. An American original equipment manufacturer (OEM), it designs and builds high performance battery-electric vehicles including trucks and aircraft. The design of all Workhorse vehicles is to make the movement of people and goods more efficient and less harmful to the environment. Workhorse Group has its corporate office in Loveland, Ohio.

In addition, the Company develops cloud-based, real-time telematics performance monitoring systems. These systems are completely integrated with its vehicles. They enable fleet operators to optimize energy and route efficiency. Workhorse Group is a leading manufacturer of medium-duty electric step vans in the United States targeting commercial fleets. The Company is the only OEM building electrified medium-duty vehicles in the United States.

Workhorse Group is developing the Workhorse W-15, the U.S.’ first light-duty pickup truck with electric powertrain targeted at commercial fleets. Target customers include delivery fleets, utility companies, telecommunications companies, municipalities and more. The Company has its N-GEN Electric Delivery Van; the W-15 electric pickup truck with extended range; the E-Gen Step Van; the SureFly™ Helicopter; the HorseFly™ Autonomous Drone Delivery System; and the METRON™ Telematics and Asset Tracking Software.

The Company designs and produces battery-electric power trains in its 50,000 sq. ft. facility in Loveland for its new Workhorse chassis. Its approach to building its battery electric power trains uses proven, automotive-grade, mass-produced parts together with its custom designed, proprietary control software. Workhorse Group received a patent in Q1 2018 for the HorseFly™ truck-launched drone delivery system from the United States Patent and Trademark Office (USPTO).

In October, Workhorse Group announced that the Workhorse NGEN-1000, a new light-weight electric delivery vehicle, entered initial production. The NGEN-1000's curb weight is 4,000lbs – less than one-half of what a traditional diesel step-van weighs – while carrying the same cubic footage of storage, 1,000 cubic feet. The NGEN will be available in four cargo sizes for customers. These sizes are 250, 450, 700 and 1,000 cubic feet.

Workhorse electric vehicles have now logged millions of miles. Moreover, they are deployed with customers across 20 states. This calendar year, greater than 100,000 packages have been delivered by Workhorse-employed drivers and delivery associates in real-world, on-road testing of Workhorse electric vehicles.

Workhorse Group, Inc. (WKHS), closed Tuesday's trading session at $0.7471, down 0.93%, on 65,727 volume with 222 trades. The average volume for the last 3 months is 221,960 and the stock's 52-week low/high is $0.69/$3.45.

chart

Black Sea Copper & Gold Corp. (BLSSF)

InvestorsHub, Barchart, MarketWatch, Stockhouse, and Investors Hangout reported on Black Sea Copper & Gold Corp. (BLSSF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Black Sea Copper & Gold Corp. is a mineral exploration company headquartered in Vancouver, British Columbia. It is active in the Black Sea region of Eastern Europe. The Company’s dedication is to build a strong portfolio of high quality copper and gold projects with the potential to become world-class mining assets. Black Sea Copper & Gold has established a complement of local technical, logistical, community, and corporate support. The Company’s shares trade on the OTC Markets Group’s OTCQB.

Black Sea’s mission is to quickly grow and advance a successful portfolio of projects in the West Tethyan Metallogenic Belt of Eastern Europe via discovery, acquisitions, and partnerships. The Company’s projects include Kalabak, Copper-Gold; and Zlatusha, Copper-Gold.

Kalabak (100 percent owned) is about 10 km north of Ada Tepe in the Bulgarian Rhodope Mountains. Mineral potential at Kalabak was identified during the Company’s extensive reconnaissance exploration program in Bulgaria. As a result, Black Sea applied for and was awarded the Kalabak license in October of 2014. The Kalabak license area (191 km2) lies within a developing porphyry copper-gold belt in the south-eastern sector of the Bulgarian Rhodope Mountains.

Zlatusha is approximately 40 kilometers northwest of Sofia in western Bulgaria within the Srednogorie endowed arc segment of the West Tethyan Metallogenic Belt. The Zlatusha license area (195 km2) lies within a developing porphyry copper-gold/epithermal belt situated northwest of Sofia. The project opportunity was identified by Black Sea Copper & Gold in July of 2013 after launching a detailed exploration campaign.

Black Sea Copper & Gold’s project pipeline includes Golaka, Copper-Gold, which is roughly 1 km from the Assarel Mine in the Panagyurishte Cu-Au trend in central Bulgaria. Also, its project pipeline includes Coka Njalta, Copper-Gold, located about 5 km south of the Majdanpek Mine in the world-class Timok belt of eastern Serbia. Additionally, the Company’s project pipeline includes Susulajka, Copper-Gold, situated roughly 12 km north of the Bor Mine in the world-class Timok belt of eastern Serbia.

In February of 2017, Black Sea Copper & Gold announced exploration results for its Kalabak property in the Bulgarian Rhodope Mountains. Field mapping and sampling results at Kalabak confirmed the presence of a porphyry environment and discovered three new structural zones with mineralization and vein textures indicative of an epithermal environment.

In October 2017, Black Sea Copper & Gold announced that following the issuance of its formal license, it signed a three-year Exploration Agreement with the Ministry of Energy for its Kalabak project. The Agreement has been followed with approvals from Bulgaria’s Ministry of Environment and Water permitting Black Sea Copper & Gold to start its comprehensive exploration program at Kalabak. The Company is undertaking a program of structural mapping, soil, and rock sampling over 10 kilometers of prospective host rocks and areas of regional structural complexity targeting Ada Tepe style epithermal mineralization.

Black Sea Copper & Gold has demonstrated its ability to identify new copper-gold porphyry and epithermal targets. It believes that it has one of the most extensive proprietary geological/exploration databases for Eastern Europe in the industry. Black Sea has more than four years of regional experience technically and operationally within Bulgaria, Serbia, Turkey, and Romania.

Black Sea Copper & Gold Corp. (BLSSF), closed Tuesday's trading session at $0.039, up 1.83%, on 806 volume with 2 trades. The average volume for the last 3 months is 763 and the stock's 52-week low/high is $0.0251/$0.1203.

chart

Kalytera Therapeutics, Inc. (KALTF)

Penny Stock Hub, The Street, OTC Markets, InvestorsHub, 4-Traders, Stockhouse, Stockwatch, Dividend Investor, Proactive Investors, YCharts, Capital Network, OTC.Watch, Investing, Marketbeat, Investors Hangout, and Barchart reported previously on Kalytera Therapeutics, Inc. (KALTF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Kalytera Therapeutics, Inc. is pioneering the development of a next generation of cannabinoid therapeutics. It is working to establish a leading position in the development of novel cannabinoid medicines for an assortment of vital unmet medical needs, with an initial concentration on Graft versus Host Disease (GvHD). A clinical-stage pharmaceutical company, Kalytera Therapeutics has its U.S. headquarters in Novato, California. The Company’s research facility is in Israel.

In addition, Kalytera Therapeutics is developing a new class of proprietary cannabidiol (CBD) therapeutics. Its intention is to explore the use of CBD, a non-psychoactive cannabis constituent. Kalytera is working to advance a portfolio of synthetic, non-psychoactive cannabis-like molecules. Furthermore, the Company will focus on orphan conditions, with the objective of generating data in humans that may support follow-on studies in major conditions.

Kalytera Therapeutics has received approval from the Institutional Review Board (IRB) at one of two clinical sites in Israel. This is to commence a Phase 2 study to evaluate cannabidiol (CBD) for the prevention of GvHD. The proposed study is a Phase 2, open label, multicenter trial. The trial is to evaluate the pharmacokinetic profile, safety, and efficacy of multiple doses of CBD for the prevention of GvHD following allogeneic hematopoietic cell transplantation (HCT). The proposed study will take place at the Rabin Medical Center, Beilinson, and the Rambam Health Care Campus, Haifa, in Israel.

The expectation is that Kalytera Therapeutics’ continuing Phase 2b clinical study evaluating the use of CBD in the prevention of GVHD will be completed early 2019. Upon completion of the Phase 2b clinical study, the Company will begin preparations for the pivotal Phase 3 clinical study that will be required for Food and Drug Administration (FDA) approval.

Kalytera announced this past July that it entered into an agreement with Beetlebung Pharma, Ltd. (BPL) for an option to acquire all rights to medical cannabis products in development by BPL for the treatment of dermatologic diseases and women's health. With the agreement, Kalytera will have the option to license from BPL certain proprietary medical cannabis formulations, which can initially be brought to market in jurisdictions that have already approved access to cannabis for medical purposes. Kalytera Therapeutics’ belief is that this will provide a more near-term path to revenues, in comparison to the longer process required for commercialization following FDA approval.

The work that Kalytera Therapeutics is doing in GVHD comprises two separate product development programs. One is a program evaluating CBD for the prevention of acute GVHD. A separate program is evaluating CBD for the treatment of acute GVHD. There is some overlap between the two programs in terms of the data that will be required for FDA registration and marketing approval. Nonetheless, the Phase 2 and Phase 3 clinical studies for each of these two programs will be separate and distinct. Kalytera’s program in prevention of acute GVHD is more advanced than is the program in treatment of acute GVHD.

Kalytera Therapeutics is the exclusive licensee of two issued U.S. patents encompassing the use of CBD in the prevention and treatment of GVHD. The Company is also the exclusive licensee of pending patent applications in other jurisdictions for the use of CBD in the prevention and treatment of GVHD.

Kalytera Therapeutics, Inc. (KALTF), closed Tuesday's trading session at $0.0733, down 5.76%, on 90,825 volume with 23 trades. The average volume for the last 3 months is 285,134 and the stock's 52-week low/high is $0.056/$0.454.

chart

Kiwa Bio-Tech Products Group Corporation (KWBT)

Wallstreetlivechat, Penny Stock Rumble, StockMister, The Penny Play, Equities, SmallCapVoice, Lions of Wall Street, Fast Moving Stocks, Darth Trader, The Stock Psycho, Top Gun and OTC Picks reported earlier on Kiwa Bio-Tech Products Group Corporation (KWBT), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Kiwa Bio-Tech Products Group Corporation is a manufacturer centering on eco-friendly bio-based fertilizers promoting soil health. It develops, manufactures, distributes, and markets novel, cost-effective and environmentally safe bio-technological products for agricultural and environmental conservation. Organic, ecologically sound, and "green" practices are the Company’s theme. OTCQB-listed, Kiwa Bio-Tech Products Group is based in Claremont, California.

Kiwa`s commitment is to eco-agricultural development and environmental control through developing, producing, and selling bio-technological products with high technology, low-cost, and high productivity to satisfy growing market demand. The Company’s dedication is to making safe food, further developing eco-agriculture, and upholding a responsibility of contributing to China's agricultural safety, food safety, and a healthy lifestyle.

The design of Kiwa Bio-Tech’s products is to enhance the quality of human life through boosting the value, quality, and productivity of crops and reducing the negative environmental impact of chemicals and other wastes. Kiwa uses new bio-technological skills at its core. Its new products structure includes 16 kinds of products in 5 major categories. These categories are Biological Organic Fertilizer, Compound Microorganism Fertilizer, Microorganism Bacterium Agent, Biological Soluble Fertilizer, and Organic-Inorganic Compound Fertilizer.

Kiwa Bio-Tech has a strategic cooperation agreement with the Beijing Zhongpin Agricultural Science and Technology Development Center (Zhongpin Center). Through the guidance and support by the Zhongpin Center, Kiwa will participate and be involved in China's National Soil Remediation Program and the building of the National Ecological Security Agriculture Industrial Chain Standardization System's operation and process.

Kiwa Bio-Tech launched a joint venture (JV) with Zhongshi'an Agricultural Science & Technology Co., Ltd. and Xintaitianyi Financial Service and Science & Technology Co., Ltd. The name of the JV is Inner Mongolia Jingnong Investment Management Co. Ltd. Moreover, as of May 15, 2018, Kiwa Bio-Tech has established four retail outlet stores in Shaanxi Province, which distribute its fertilizer products.

Last month, Kiwa Bio-Tech Products Group announced that it received approval from the Yangling Free Trade Zone in China to obtain land for the construction of a manufacturing facility to meet the US$16 billion-dollar increasing demand for bio-fertilizers in China over the next 5 years. This manufacturing facility will specialize in developing and producing the Company’s core microbes, the fundamental components for making high-quality bio-fertilizers. The facility will have a production capacity of 60,000 tons of Kiwa Bio-Tech’s core microbes with a yearly production value estimated to be greater than US$65 million dollars (about 462 million RMB).

Today, Kiwa Bio-Tech Products Group announced its financial results for the three months ended September 30, 2018. Q3 financial results highlights include record quarterly Revenue in Q3 2018 of $7,725,583 and record quarterly Gross Profit in Q3 2018 of $2,273,458.

Kiwa Bio-Tech Products Group Corporation (KWBT), closed Tuesday's trading session at $0.40, down 32.20%, on 1,650 volume with 1 trade. The average volume for the last 3 months is 8,009 and the stock's 52-week low/high is $0.27/$2.50.

chart

Biotricity, Inc. (BTCY)

Stock News Now, InvestorsHub, 4-Traders, Finance Registrar, SmallCap Network, Stockhouse, GuruFocus, Barchart, and SECFilings.com News reported previously on Biotricity, Inc. (BTCY), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Biotricity, Inc. is a medical diagnostic and consumer healthcare technology company listed on the OTC Markets Group’s OTCQB. The Company’s commitment is to deliver biometric remote monitoring solutions. It delivers these solutions to the medical and consumer markets. This includes diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity is based in Redwood City, California.

The Company’s vision is putting health management into the hands of the individual. Biotricity is working to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. Biotricity’s Research and Development (R&D) continues to center on the preventative healthcare market.

Biotricity has created two ECG monitoring devices. The design of these is to improve upon the tools and devices available in the contemporary market.

For Physicians, the Company has its Bioflux. This is a medical technology solution for physicians to test and diagnose patients, and benefit from an inventive system, which provides continuing active monitoring for up to 30 consecutive days.

Bioflux consists of an ECG monitoring device, software, as well as access to a monitoring lab. The Bioflux software component is an acquisition that is already Food and Drug Administration (FDA) cleared. It is a standard for ECG monitoring in hospitals and cardiac clinics.

For Consumers, Biotricity has its Biolife. This is a preventative care solution. It leverages the expertise gained from the Company’s Bioflux.

The design of Biolife is to assist individuals in tracking their progress in real-time so they can stay motivated to make lifestyle changes. Biolife helps users make lifestyle changes through uniting medically relevant ECG data with social media interactivity and a lifestyle log.

Biotricity has partnered with Global to Local (G2L). This collaboration between Biotricity and G2L will first focus on building distinct solutions for outcome measurements for individuals suffering from chronic disease.

Yesterday, Biotricity announced that it completed the alpha version of Bioflux 2.0’s deep data diagnostic solution in accordance with FDA arrhythmia diagnostic standards. Biotricity’s intention is to take advantage of its new artificial intelligence (AI) and deep data technology in arrhythmia analysis in its Bioflux 2.0 solution and concentrate on improved accuracy, faster diagnostics for patients, more efficient monitoring, and improved call center efficiency.

Biotricity, Inc. (BTCY), closed Tuesday's trading session at $1.10, up 3.77%, on 109,738 volume with 120 trades. The average volume for the last 3 months is 110,381 and the stock's 52-week low/high is $0.942/$19.50.

chart

Canarc Resource Corp. (CRCUF)

FeedBlitz, ShazamStocks, CrushTheStreet, Baby Bulls, AllPennyStocks, Research Driven Investor, FutureMoneyTrends, SmallCapVoice, and Stockhouse reported on Canarc Resource Corp. (CRCUF), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Canarc Resource Corp. is a growth-oriented, gold exploration and mining company based in Vancouver, British Columbia. It is presently concentrating on acquiring operating or pre-production stage gold-silver-copper mines or properties in the Americas and further advancing its gold properties in north and central British Columbia. Canarc Resource’s shares trade on the OTC Markets Group’s OTCQB.

Canarc’s core Gold Project asset is the 100 percent owned, past-producing, high-grade New Polaris gold mine project in northwestern British Columbia. Based on an updated NI (National Instrument) 43-101 resource estimate using a 6 gpt gold cutoff grade, the New Polaris property currently contains measured and indicated resources of 519,000 oz gold contained in 1,288,000 tonnes grading 12.5 gpt gold.

New Polaris contains inferred resources totaling 636,000 oz gold contained in 1,628,000 tonnes grading 12.2 gpt gold. It is still open for expansion in other veins and at depth. New Polaris is the Company’s most advanced gold mine project.

In addition, the Company has its Windfall Hills gold project. Windfall Hills is 65 kilometers south of Burns Lake and 90 kilometers’ northwest of Richfield Ventures’ Blackwater gold discovery in central British Columbia. The Windfall Hills project encompasses claims totaling 3879 hectares.

Canarc Resources, subsequent to receiving regulatory approvals, closed the definitive agreement with Eureka Resources, Inc, pursuant to which Canarc has an exclusive option to acquire up to a 75 percent interest in the FG Gold Property positioned roughly 100 kilometers east of Williams Lake in central British Columbia.

The Company is continuing its strategy to acquire more advanced and/or near-term gold mining projects located in the Americas. It is working to develop a Phase 2 exploration plan at Fondaway Canyon for near term production potential.

In 2017, Canarc Resource completed the acquisition of a portfolio of ten gold exploration properties in Nevada with historic gold resources and considerable exploration potential significantly enhancing Canarc’s potential for new discoveries and resource expansions in the jurisdiction of Nevada.

Recently, Canarc Resource announced that it engaged Hatch Ltd. to evaluate the feasibility of installing and operating a small concentrate autoclave at Canarc’s New Polaris mine site as part of a process plant to produce gold dore bars onsite. Hatch is an international engineering company.

New Polaris has no road access. Therefore, if building and operating an autoclave is economic to produce gold dore bars onsite, this project can be remodeled as a fly in-fly out operation with seasonal barging, a possible significant breakthrough for advancing the project towards production.

Canarc Resource Corp. (CRCUF), closed Tuesday's trading session at $0.03025, up 4.67%, on 135,000 volume with 7 trades. The average volume for the last 3 months is 36,766 and the stock's 52-week low/high is $0.0239/$0.0784.

chart

The QualityStocks Company Corner

Zenergy Brands, Inc. (ZNGY)

The QualityStocks Daily Newsletter would like to spotlight Zenergy Brands, Inc. (ZNGY).

In just one generation, digitalization has transmogrified the world. With streaming movies, it has brought the cinema into our homes. E-commerce has done the same for main street retailing. Also, social media seems to have made geographical location redundant; it’s as easy to communicate with someone in Timbuktu as it is with a neighbor down the street. Now, with “virtual utility” companies like Zenergy Brands, Inc. (OTC: ZNGY), digitalization is giving us a way to consume energy more efficiently and responsibly. Zenergy has developed a suite of cost-saving energy solutions utilizing the latest digital technologies.

Zenergy Brands, Inc. (ZNGY) is the nation’s leading next-generation energy and technology company operating in the emerging smart energy, conservation, and utility industries. Headquartered in Texas, Zenergy provides an entire suite of conservation-based products and services that enable clients to achieve sustainability goals, reduce carbon emissions and improve their bottom line. The company’s cutting-edge Zero Cost Program™ reduces utility expenses by 20 percent to 60 percent by offering energy conservation, smart controls, and efficiency-based products and services to residential, commercial, industrial and municipal end-use customers.

The Zero Cost Program™ is a financing mechanism that allows customers to reduce water, natural gas and electricity expenses by implementing proven conservation technologies at no out-of-pocket cost. The Zero Cost Program™ enriches businesses by immediately reducing energy consumption through the use of smart controls, building automation, LED lighting solutions, refrigeration optimization, efficient water systems, EC motor controls, demand-side management and load factor correction.

A unique Managed Energy Services Agreement (“MESA”) allows a portion of these utility savings to be retained by Zenergy’s partner financing the upgraded, retrofit equipment and installation costs until a specified repayment period ends. After that, clients reap all the financial rewards of the technologies implemented, which Zenergy estimates should range between 25 percent and 45 percent of total utility costs.

Residential customers seeking cost-effective energy savings can also choose from a suite of “Smart Home” products including home automation, security monitoring, and energy conservation services that can be controlled 24/7 from the comfort and convenience of their smartphones or internet-connected smart devices. Zenergy’s residential program offers partnership opportunities for homebuilders and residential, multi-family real estate developers to provide smart home technologies to high-end customers.

Zenergy Brands’ acquisition of Enertrade Electric LLC, a fully operating, licensed Texas-based Retail Electric Provider (REP), further increases the company’s value proposition. Zenergy CEO Alex Rodriguez said this new subsidiary adds an essential complementary service to the company’s suite of smart energy products and services.

“Since our founding, our vision has been to converge smart controls (home and building automation) with energy conservation and retail energy to deliver the comprehensive smart energy service to customers,” Rodriguez said.

On a global scale, residential and commercial buildings account for nearly 45 percent of the world’s total energy consumption. Improving the energy efficiency of these homes and buildings is often a more affordable way to reduce harmful gas emissions while minimizing the need for new energy production. According to Navigant Research, global revenue for energy-efficient commercial building retrofits alone is expected to grow from $71.4 billion in 2016 to $100.8 billion in 2025. At the same time, the energy-efficient devices market is expected to reach a market size of $908 billion by 2022. Increasing demands for reduction in energy consumption and greenhouse gas emissions along with concerns over climate change are contributing factors driving the market’s overall growth.

Zenergy Brands, Inc. (ZNGY), closed the day's trading session at $0.000195, off by 2.50%, on 104,225,000 volume with 6 trades. The average volume for the last 3 months is 20,471,581 and the stock's 52-week low/high is $0.000192/$0.029.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. The Company's President and CEO, Mr. Richard T. Schumacher, joined Stock Day's Mr. Everett Jolly to announce the achievement of yet another important milestone in the advancement of its proprietary Ultra Shear Technology (UST) platform and commercialization program.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.30, up 13.79%, on 3,292 volume with 15 trades. The average volume for the last 3 months is 2,910 and the stock's 52-week low/high is $2.59/$5.00.

Recent News

chart

Sproutly Canada, Inc. (OTC: SRUTF) (CSE: SPR) (FRA: 38G)

The QualityStocks Daily Newsletter would like to spotlight Sproutly Canada, Inc. (SRUTF).

Sproutly Canada, Inc. (CSE: SPR) (OTCQB: SRUTF) (FSE: 38G) ("Sproutly" or the "Company") is pleased to announce that the license of its wholly-owned subsidiary, Toronto Herbal Remedies Inc. ("THR") under the Access to Cannabis for Medical Purposes Regulations ("ACMPR") has been migrated to the Cannabis Act and its regulations. The issuance of the new cannabis license includes the ability to sell cannabis to other licensed producers in accordance with subsection 11(5) of the Cannabis Regulations.

Sproutly Canada, Inc. (OTC: SRUTF) (TSX.V: SPR) (FRA: 38G) is developing and bringing to market cannabis consumer products with a focus on beverages. The company’s core mission is to become the leading supplier of water-soluble cannabis solutions and bio-natural oils for brands in the emerging cannabis beverage and edibles market.

To make this happen, Sproutly acquired Infusion Biosciences to bring to market a patent-pending Aqueous Phytorecovery Process (APP) technology, a fundamental paradigm shift within the cannabis industry. Replacing traditional water-compatible solutions with true natural water solubility improves the body’s ability to utilize cannabinoids, making the effect of the cannabis almost immediate.

This revolutionary process doesn’t alter the cannabis compounds and provides an onset time and offset time that mimics the same effects as inhaled marijuana. That means consumers may feel effects in five minutes or less and be free from the desired effect in approximately 90 minutes—a vastly different ingestion pattern than current methods. In addition, the water-based cannabinoids can be mixed with other liquids and stay dissolved in those liquids. The application of water-soluble cannabis infusions has potential to be widespread in both medicinal and recreational cannabis sectors, giving Sproutly a distinctive edge in a market with untapped potential.

Sproutly’s business model is focused on processing rather than cultivating, which means its success is not constrained to growing its own cannabis. The company does own a Toronto-based, ACMPR-licensed facility designed and built with a focus on cultivating pharmaceutical-grade cannabis to produce and formulate the first natural, truly water-soluble cannabis solution. Its water-soluble ingredients and bio-natural oils will deliver revolutionary brands to international markets that are searching for well-defined commercial products.

Sproutly’s entrance in the cannabis market is perfectly timed as cannabis is moving towards mainstream acceptance. Potential users are, however, interested in consuming cannabis products as drinks and using it as oils rather than smoking. The potential cannabis beverage market is staggering, and with Sproutly owning the exclusive rights to APP technology in Canada, Australia, Jamaica, Israel and the entire European Union, the company is looking at significant international expansion opportunities.

Sproutly plans to capitalize on these international opportunities by executing on partnerships with local and globally established consumer brands to leverage their existing customer bases, expand brand loyalty, and assist with marketing and support distribution networks to deliver scientific breakthroughs with speed and efficiency?worldwide.

Management

Sproutly believes that talent drives growth. The company is committed to bringing together the best and brightest minds in the cannabis space to help with their mission to disrupt the global beverage and consumables market.

President, CEO and Director Keith Dolo recently served for more than 13 years with Robert Half, an S&P 500, NYSE-listed company. At Robert Half, Dolo held the position of vice president for more than eight years, as well as other senior roles in both operations and sales. He also sits on an advisory committee and a board position for two nonprofits in Vancouver, BC.

Chief Science Officer and Director Dr. Arup Sent has more than 35 years of experience in research and executive management at biotechnology and pharmaceutical companies. He was awarded a PhD in biochemistry from Princeton University and is a former faculty member at the National Cancer Institute and Scripps Research Institute. Sen is the inventor on five U.S. patents and numerous international patents and patent-pending applications.

Chief Financial Officer Craig Loverock is a chartered professional accountant with over 20 years of experience in accounting and finance roles in Canada, the United States and the United Kingdom. He has extensive expertise in public company reporting and transactional experience, having served as the senior financial advisor to the chairman at Magna International and acting as chief compliance officer and CFO for a private equity firm.

Head Grower Frank Han has over 12 years of experience in the horticulture industry. A previous master grower in a large commercial facility, Han has impressive expertise in all growing methods, techniques and procedures. He brings with him a wealth of knowledge in cloning, nutrient and overall plant management. Han will be in charge of the production team at Sproutly’s Toronto Herbal Remedies facility.

Sproutly Canada, Inc. (OTC: SRUTF), closed the day's trading session at $0.30, up 7.53%, on 74,592 volume with 76 trades. The average volume for the last 3 months is 130,547 and the stock's 52-week low/high is $0.279/$1.875.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF) was highlighted today in a report on how the medicinal uses niche of the cannabis industry continues to generate strong revenues as consumers are searching for alternative treatments and natural solutions for various health issues and conditions.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $2.3703, off by 1.65%, on 671,052 volume with 1,115 trades. The average volume for the last 3 months is 1,513,169 and the stock's 52-week low/high is $1.87/$7.89.

Recent News

chart

NUGL Inc. (NUGL)

The QualityStocks Daily Newsletter would like to spotlight NUGL Inc. (NUGL).

NUGL Inc. (NUGL) was featured today in a report by CannabisNewsWire examining how current research shows that the reproductive system of females is second only to the brain in terms of having the biggest number of endocannabinoid receptors within the body.

NUGL Inc. (NUGL) is focused on leading the evolution in business relations, development and organic data in the cannabis industry with a distinct platform. In this effort, it has developed a leading-edge, first of its kind search app and online directory for the marijuana industry that provides a one-stop source and listings for dispensaries, strains, doctors, lawyers, service professionals, vape shops, hydro stores and brands.

Headquartered in Chino Hills, California, which is home to a projected $5 billion legal marijuana marketplace, NUGL is on track to become a major asset for the global cannabis industry and related services sectors. The company recently established a strategic partnership with Thinklogic and appointed CEO Chris Adams to NUGL’s growing board of directors. Thinklogic is a top-level software development company specializing in projects for start-ups to Fortune 500 companies.

“This strategic partnership puts NUGL in a distinguished class, adding a first-rate technical software expert like Chris gives NUGL a unique technological advantage,” said Brandon Vargas CEO of NUGL. “With the addition of Chris’s knowledge and expertise combined with Thinklogics’ experienced and skilled staff, NUGL will have the ability to evolve and build a strong infrastructure unmatched in the 420 industry.”

NUGL is nearing completion of its initial launch timeline, with plans to launch the app on both Android and iOS platforms within the next few weeks. NUGL’s live testing of its software includes enhanced reviews that detail up to 10 category ratings. Each of the category rankings allow users to leave comments and choose among a 5-star rating among all categories or as few as they wish. The software’s rating platform allows for customization and transparency for users while providing invaluable feedback to shops and professional services.

“This is a major feature that is critical to our community,” said Jeff Odle, NUGL’s CTO. “Enhanced ratings will be a definitive difference validating our organic listings and raising the standard for the industry. We want the users to know what they are getting before they step into a store or sign up for a service.”

Leadership Team

NUGL is growing its team of developers and launching new features on an ongoing basis. The company is ahead of an impressive timeline, which includes building blocks for scalability and massive growth.

“Everything we do is focused on user experience. Our philosophy is simple – make it fun and easy to use, with the purest and most unbiased results,” said Ryan Bartlette, NUGL CMO. “As the industry evolves and becomes more sophisticated, NUGL will adapt and build the best marketing technology for the cannabis-related companies. We have gotten in on the ground level and know the pulse of the industry.”

NUGL CEO Brandon Vargas is a founding member of G6 Management, a full-service consulting firm advising cannabis professionals in all aspects of business. With over 10 years’ experience in the cannabis space, he has worked on dispensary, cultivation and infusion entity formation, licensing, real estate acquisitions, construction and build out, marketing, policy and procedures, compliance, staffing, and capital raises. Vargas has an extensive background working with various medical marijuana companies on investment and in developing greenhouse and commercial cultivation, distillate for vapes cartridges, CBD oils and infusions.

CMO Ryan Bartlette is co-founder and CMO of 23Forty LLC and Boxy. He has expertly positioned and branded many companies while bringing them to market and is a sought out graphic artist, front-end developer, photographer, and visual artist with experience in the entertainment and technology industry.

Jeff Odle, NUGL CTO, is a successful senior software architect has a long and distinguished career developing some of the most innovative, cutting-edge platforms available. His unique and distinctive approach to creating the blueprint for advanced programming is industry leading and unprecedented. He is a top-level architect responsible for developing some of the most forward-­looking software for various industries.

NUGL’s board of directors includes John R. Armstrong, a founding partner of Horwitz + Armstrong, a full service general business firm handling all aspects of litigation and business strategy and advice. Armstrong and his partner, Lawrence Hortwitz, have more than 10 years of experience in the cannabis space, representing cannabis professionals in all aspects of business including business formation, licensing, compliance with local and state regulations, real estate acquisitions, corporate mergers and acquisitions, financing, inclusive of capital raises and alternative financing, contracts, and all forms of dispute resolution.

Board member Hendrik Klein, founder of Da Vinci Asset Management, a privately-owned investment firm, serves as CEO and executive board member of Fritz Nols AG, a capital marketing consulting firm specializing in trading and asset management. Klein has received several industry awards including the Austrian Hedge Fund Award, the German Hedge Fund Award, and most recently was named the Global Best Performing Systematic Quantitative CTA. Klein and the Da Vinci team employ the latest quantitative data research and analysis in their innovative investment strategy.

NUGL Inc. (NUGL), closed the day's trading session at $1.955, off by 0.26%, on 74,485 volume with 68 trades. The average volume for the last 3 months is 194,061 and the stock's 52-week low/high is $0.405/$2.64.

Recent News

chart

CytoDyn Inc. (CYDY)

The QualityStocks Daily Newsletter would like to spotlight CytoDyn Inc. (CYDY).

CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that the United States Adopted Names (USAN) Council has adopted leronlimab as the official name for PRO 140.  Leronlimab is an investigational new drug and has not yet been approved for any indication.

CytoDyn Inc. (CYDY) is a biotechnology company focused on the clinical development and potential commercialization of a new class of HIV/AIDS therapeutics or viral-entry inhibitors intended to protect healthy cells from viral infection. The company’s pipeline includes its lead product, PRO 140 for multiple indications among which are human immunodeficiency virus (HIV), graft-versus-host disease (GvHD), colon cancer, and multiple sclerosis (MS), each in various stages of development. CytoDyn first approval is focused on HIV indications for two different HIV populations.

PRO 140 is a humanized monoclonal antibody directed at CCR5, a molecular portal that HIV uses to enter T-cells. PRO 140 works by blocking the predominant HIV (R5) subtype entry into T-cells by masking this required co-receptor, CCR5.

CytoDyn has completed one pivotal phase 3 clinical trials of PRO 140 use in combination with current drugs for population that has limited treatment options. PRO 140 is also currently in another phase 3 (investigative trial) for a second approval for another HIV population. HIV continues to be a major global public health issue. There is no cure for the disease that has claimed more than 35 million lives to date, according to the World Health Organization (“WHO”). In 2017, 940,000 people around the world died from HIV-related causes. There were approximately 36.9 million people living with HIV at the end of 2017 with 1.8 million people becoming newly infected during that same year. The WHO estimates there were 21.7 million people globally receiving antiretroviral therapy (“ART”) in 2017.

HIV targets the immune system and weakens the body’s defense systems against infections and some types of cancer. As the virus destroys and impairs the function of immune cells, infected individuals gradually become immunodeficient which results in increased susceptibility to a wide range of infections, cancers and other diseases that people with healthy immune systems can fight off. The most advanced stage of HIV infection is Acquired Immunodeficiency Syndrome (AIDS), which can take from 2 to 15 years to develop depending on the individual.

PRO 140 functions by blocking the HIV co-receptor CCR5, a molecular portal HIV uses to enter T-cells, thus preventing the HIV virus from entering the cell. CCR5 is a protein located on the surface of white blood cells that normally serves as a receptor for chemicals that attract immune cells to the site of inflammation. Clinical trials to date indicate PRO 140 does not interfere with these normal CCR5 functions. Results from phase 1 and phase 2 human clinical trials have shown PRO 140 significantly reduces viral burden in people infected with HIV. Importantly, in a recent phase 2b clinical trial, PRO 140 demonstrated it can allow a subset of R5 strain of HIV population to replace their current HIV regimen (Highly Active Antiretroviral Therapy or “HAART.”) by a simple sub-cutaneous self-injectable dose of PRO 140 which is administered once a week. Some of those patients have received PRO 140 as their only therapy for almost four years.

The PRO 140 antibody appears to be a powerful antiviral agent with hardly any side effects, toxicity. More than 500 patients have used PRO 140 in clinical trial and no resistance has ever been developed in any patients including patients in monotherapy of PRO 140 for almost four years.

PRO 140, which is taken as an easy-to-use, weekly, subcutaneous self-administered dose, has almost no side effects or toxicity with no report of any serious adverse event related to PRO 140 in more than 500 patients in eight different clinical trial.

As we indicated earlier patients given PRO 140 showed no drug resistance on monotherapy for some almost four years while 76% of HAART patients developed a resistance to some portion of the lifetime drug regimen. Patient compliance with HAART is also the main reason why only 35% of HIV patients in US reporting complete viral load (VL) suppression which is VL<50 cp/mL.

In addition to its research into the powerful potential of PRO 140 for use in HIV patients, CytoDyn is pursuing PRO 140 as a therapeutic anti-viral agent in other non-HIV indications that could benefit from PRO 140’s ability to block CCR5. These immunologic indications include new reactions to cancer, transplantation rejection, autoimmune diseases and chronic inflammation such as Multiple Sclerosis. The company sees the significant potential for multiple pipeline opportunities for PRO 140.

The U.S. Food and Drug Administration has designated PRO 140 as a “fast track” product for HIV and granted Orphan Drug Designation to it for the prevention of GvHD in transplant patients. CytoDyn has initiated its first clinical trial with PRO 140 in an immunological indication for GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation. The company is also investigating PRO 140 in animal models of cancer progression and autoimmunity with positive results and has published its animal study results in GvHD in peer-reviewed journal.

CytoDyn president and CEO Nader Z. Pourhassan, Ph.D. joined the company in 2008 and is credited for purchasing PRO 140 from Progenics in 2012 and has taken a new path to approval for the product. He is the co-inventor of monotherapy path for PRO 140. He has taken PRO 140 development from phase 2 to Completed successful phase 3 in about four years. He now has more than 10 years of drug development experience and has overseen the rapid clinical development of PRO 140 as a therapy for HIV into two phase 3 for two different indications. He also initiated PRO 140 first immunological indication in GvHD (currently in phase 2). He is also involved in preclinical and clinical development of PRO 140 in additional immunological indications.?Dr. Pourhassan, who has more than 20 years of business development experience, has led CytoDyn’s capital market activities since joining the company in 2008. He received his Bachelor of Science from Utah State University, Master of Science from Brigham Young University, and his Ph.D. in Mechanical Engineering from the University of Utah and is the author of three books.

CytoDyn Inc. (CYDY), closed the day's trading session at $0.595, off by 2.44%, on 409,476 volume with 123 trades. The average volume for the last 3 months is 235,675 and the stock's 52-week low/high is $0.40/$0.84.

Recent News

chart

Green Hygienics Holdings Inc. (GRYN)

The QualityStocks Daily Newsletter would like to spotlight Green Hygienics Holdings Inc. (GRYN).

Green Hygienics Holdings (OTC: GRYN), a full-scope, premium cannabis company, sees its rebranded Cannagram Services as a key platform to generate strategic growth in vertical markets. To view the full article, visit: http://nnw.fm/SC2lO.

Green Hygienics Holdings Inc. (GRYN) is a full-scope, premium cannabis cultivation company targeting the high-end medical and adult-use recreational market. With more than 25 years of experience in agricultural science and innovation, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company will grow by generating revenues from the sales of premium grade cannabis products, developing and licensing valuable IP, making strategic acquisitions, and creating trusted global consumer brands.

The company has integrated and is developing its own IP assets related to proprietary systems and apparatus, software, algorithms and custom-engineered hardware. This provides ultimate efficiencies in a commercially controlled cultivation environment. Utilizing the advantages of hybrid-aeroponics, Green Hygienics creates a sterile growing environment that produces consistent, high-quality product while maintaining the lowest possible carbon footprint. The company utilizes state-of-the-art, quality-controlled commercial cultivation methodology to assure production of pharmaceutical-grade cannabis at much higher yields and greatly reduced costs.

Hybrid-aeroponics produces quality cannabis faster than traditional methods since it doesn’t require natural sunlight or soil and can be operational and produce plants anywhere. Plants grown under aeroponic conditions receive water and nutrients directly to their roots via a fine mist in a controlled environment, dramatically reducing spoilage while keeping the product organic and the environment pest-free. The plants are given the exact amount of nutrients and moisture precisely when needed. Green Hygienics maintains ultimate control over every aspect of this cultivation process, which allows the company to operate with conservation of natural resources in mind. The technology that uses 90-95 percent less water and does not require the use of pesticides or fungicides.

Additionally, the company’s state-of-the-art engineered, controlled environments include electrical, mechanical and HVAC designs that meet mandatory fire and energy codes while improving energy efficiency significantly.

Through these practices, Green Hygienics is establishing itself as a leader in the advancement of science-driven cannabis cultivation systems. The company continues to develop and incubate software as well as engineer hardware to provide additional control over the commercial cultivation method. The company’s science-based approach reveals any growth anomalies before the human eye can see them. This makes it possible to monitor all facets of production, identify cultivation problems based upon scientific data, and implement immediate corrective action, if needed.

The future of commercial cannabis cultivation hinges on using science to control the growing environment in order to remain competitive and deliver a premium grade of product on a consistent basis. The company holds a competitive advantage through its ability to produce premium cannabis products at a significantly lower cost per gram than direct competitors and others in the cannabis industry.

Innovations within the sector that create efficiencies and successful brands will become highly valued. Green Hygienics and its forward-thinking management team are constantly studying the market dynamics of the cannabis industry in North America and abroad while actively pursuing possible expansion opportunities. The company is headquartered in Las Vegas, Nevada and establishing operations in San Diego, California, targeting the $5 billion California cannabis market.

Green Hygienics Holdings Inc. (GRYN), closed the day's trading session at $0.46, off by 2.11%, on 1,600 volume with 1 trade. The average volume for the last 3 months is 32,535 and the stock's 52-week low/high is $0.009/$0.508.

Recent News

chart

Choom Holdings Inc. (CSE: CHOO) (OTC: CHOOF)

The QualityStocks Daily Newsletter would like to spotlight Choom Holdings Inc. (CHOOF).

Choom (CSE: CHOO) (OTCQB: CHOOF) (the "Company" or "Choom") an emerging adult use cannabis company that has secured one of the largest national retail networks in Canada, is pleased to announce it has acquired Clarity Cannabis Medical Centre Inc. and affiliates doing business as Clarity Medical Centres.

Choom Holdings Inc. (OTC: CHOOF) (CSE: CHOO) channels the laid-back spirit of Hawaii to the Okanagan region of British Columbia with a generous nod to the inspirational, yet unofficial, history of the 1970s “Choom Gang,” a group of buddies in Honolulu (including former President Barack Obama) who knew how to relax with “choom,” the local’s term for marijuana. Choom’s trademark slogans pivot off another unconventional phrase (“Say Hello to…”), bringing a heady dose of good times and good friends together as the company invites investors to “Say Hello to Choom™” as it lights up the adult recreational cannabis market in Canada.

Choom™ has been an ACMPR (Access to Cannabis for Medical Purposes Regulations) applicant since November 2013 in Vernon, B.C. The company’s first application has received security clearance and is now in the detailed review stage. They also recently announced their second late-stage ACMPR application, which is in its confirmation of readiness stage. Cannabis Compliance Inc. has been retained to help expedite Choom’s initial license applications to ensure the company’s readiness for legalization of recreational marijuana in Canada mid-summer 2018.

True to the company’s character, Choom™ is retrofitting two large facilities – No. 1 in Vernon, B.C., and No. 2 on Vancouver Island – to house its cannabis growing facilities. Phase 1 of the Vernon property will provide Choom™ with 6,800 square feet of growing space, capable of producing 660 kg/year of cannabis at an estimated revenue of $6.6 million, excluding oils. The company expects this facility to be completed by July 2018, the same month that Canada is expected to formally legalize recreational marijuana for adult use. A potential Phase 2, to be completed by the end of 2018, would add another 6,800 square feet for a total of 1,500 kg/year capacity, which would nearly double No. 1’s revenue. A Level 9 vault is also planned with a storage capacity of 15,000 kg. While the No. 2 facility on Vancouver Island is smaller – 4,500 square feet – its retrofit is also slated to be completed by July 2018. Plans include doubling this space as well, which would add about $9 million in annual revenue, excluding cannabis oils.

Choom™ announced its retail dispensary strategy with the intention of establishing market leadership in reaching the Canadian cannabis consumer. The partner program is already in the retail space design stage as the company seeks to build a chain of branded retail cannabis dispensaries in jurisdictions in Canada where recreational cannabis is legal. Choom™ Stores will have a cool, modern layout and design created to emit an authentic “Aloha” vibe. Choom™ is all about producing high-grade cultivars and curating them for a bigger audience.

A savvy, experienced management team includes Chris Bogart, president and CEO; John Oh, R.P.I.C., Operations Manager; Robert Bayrack, Master Grower, S.P.I.C.; and Adrian Robinson, Strategic Advisor. Bogart has over two decades of international experience in capital markets and was a co-founder of InMed Pharmaceuticals and Magnum Uranium. He has structured complex equity financing transactions in the U.S., Europe and Canada. Bogart is joined on the Board of Directors by Kevin Pull, Stephen Tong and John Oh.

While the medical marijuana industry is expected to double by 2021 to 500,000 registered users, the true highlight of the recreational cannabis represents the key cultural shift set to launch in Canada. With an estimated $4.9B to $8.7B retail market coming, now is the right time for a Recreation Brand like Choom™ to be involved in this growing industry. Establishing and maintaining Choom™ premium brand loyalty is a key factor in the company’s growth strategy. Get ready to “Say Hello” to opportunity, good times and good friends with Choom™.

Choom Holdings Inc. (CHOOF), closed the day's trading session at $0.44148, off by 0.59%, on 350,885 volume with 290 trades. The average volume for the last 3 months is 385,826 and the stock's 52-week low/high is $0.18/$1.129.

Recent News

chart

Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF)

The QualityStocks Daily Newsletter would like to spotlight Lithium Chile Inc. (LTMCF).

Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF) was pleased to provide shareholders with an operational update today. SALAR DE COIPASA:  While Lithium Chile has successfully negotiated terms for surface access to the salar de Coipasa with the community executive, the Company is currently waiting for final approval by the community council. Once that occurs, a reconnaissance drilling program will commence immediately.  At 129 km2 (as shown on the map below) Coipasa is Lithium Chile's second largest lithium prospect upon which a very large and highly conductive target, covering 65% of the property, was identified during the geophysical survey completed in the first quarter of 2018.

Lithium Chile Inc. (TSX.V: LITH) (OTC: LTMCF), headquartered in Canada, is advancing one of the largest lithium-rich exploration portfolios in Chile consisting of more than 148,000 hectares covering sections of 13 salars or mineral salt flats and one laguna complex. The company’s wholly owned premier properties include 66 square kilometers on the Salar de Atacama, Chile’s largest mineral salt flat which hosts the world’s highest concentration of lithium brine production and is currently the source of about 35 percent of the world’s lithium production. Lithium Chile also owns a significant copper/gold/silver property portfolio consisting of 28,184 hectares over six different properties.

Lithium Chile’s portfolio in the heart of Chile’s lithium-rich salars includes Salar de Coipasa, Salar de Helados, Salar de Atacama, Salar de Turi Salar de Ollague and Salar de Talar. Surface and near surface salt and brine sampling programs on all properties has been completed. To date, samples of high-grade, near-surface lithium brines at each of these projects are showing excellent chemistry of lithium to potassium and lithium to magnesium ratios. Good chemistry is important as it reduces your overall cost of production. Recent geophysical surveys including T.E.M have been completed on 5 of 6 priority targets and data collected to date has been extremely encouraging.

Lithium Chile has identified multiple high-priority brine target areas at its Atacama and Ollague lithium project areas. These areas display the same geophysical characteristics as the lithium-rich aquifers at Salar de Atacama, home to the world’s largest and highest-grade lithium brine producers. Spanning an area of 1,200 square miles, Salar de Atacama is the world’s third largest salt flat behind Salinas Grandes in Argentina and El Salar de Uyuni in neighboring Bolivia. Exploration drilling and resource definition drilling for these target areas are planned for 2018.

“We are delighted with the discovery of such impressive drill target areas at Atacama and Ollague. The results also follow the recent discovery of a 60km2 target area at another of our top Chilean projects – Helados – where we hope to drill in the second quarter of 2018,” stated President and CEO Steve Cochrane. “We have an aggressive multi-project drill program planned for this year, which includes all three of these exciting projects and we look forward to sharing drill results as they come through.”

Global demand for lithium-ion batteries is expected to surpass US$53 billion by 2024 as governments around the world aggressively seek to ban gas-powered vehicles and major automakers invest billions in new technology and electric vehicles powered by lithium-ion batteries. Chile’s mining-friendly jurisdiction offers Lithium Chile a clear, streamlined permitting process that significantly lowers the cost of lithium production to around $1,800/ton as compared to Australia’s $5,000/ton.

Lithium Chile is led by an experienced team with strong Chilean connections. Cochrane’s 36 years of investment industry experience have primarily been focused on the mining sector. During this time, he raised more than US$500 million for a variety of small cap public companies in various businesses and industry sectors including mining.

Terry Walker, P.Geol., vice president of exploration and chief geologist, is a highly experienced geologist. He has spent over 25 years in Chile’s mining industry and is well connected throughout the sector. Walker is co-founder of GeoServicios Piedra Dorada, an exploration and development services company focused on Latin America. He is a Qualified Person for the North American and Australian stock exchanges.

Lithium Chile is well funded and driven by a top-tier team with more than 100 years of combined experience in financing, mining exploration and development in the natural resources sector.

Lithium Chile Inc. (LTMCF), closed the day's trading session at $0.414, off by 3.72%, on 7,567 volume with 9 trades. The average volume for the last 3 months is 53,752 and the stock's 52-week low/high is $0.3925/$0.97.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

British Columbia, Canada-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is a biotechnology company and developer of technology which has demonstrated faster and more effective delivery of cannabinoids and nicotine. Recently, LXRP raised funds through a non-brokered private placement that it intends to use toward the construction of a new Canadian lab, research & development and general corporate purposes. To view the full article, visit: http://nnw.fm/Me6mC.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including cannabinoids. Though boasting a wide range of health benefits, cannabinoids are traditionally poorly absorbed by the body’s gastrointestinal tract. To achieve higher effectiveness, consumers usually default to smoking. Lexaria provides a superior administration method by delivering hemp oil ingredients – or through locally licensed partners, cannabis oil ingredients – through a patented process within food products.

The key differentiator between Lexaria’s products and others on the market is the company’s disruptive technology proven to enhance the absorption of orally ingested cannabinoids while improving the “unusual” taste of cannabinoids and allowing for lower overall dosing with higher efficacy. Lexaria is primarily a B2B enterprise, and is in licensing discussions or has existing agreements with companies in Canada, the largest-market states in the USA, and internationally. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within lipids in popular foods. These brands include ViPova™, Lexaria Energy Foods, and TurboCBD™.

In 2015, Lexaria commissioned an independent, third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation both improve intestinal absorption as much as 500%. Additional follow-up studies in human volunteers suggested that Lexaria’s processed, lipid-infused tea may be more effective in an actual gastrointestinal system than in an in vitro simulation with results indicating as much as a 1,000% increase in overall absorption.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D are expected to support accelerating B2B relationships – not just in the cannabis industry, but also to support new B2B business relationships in the fields of vitamins, NSAIDs, and nicotine delivery. All of these sectors expected to offer additional future growth potential.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong intellectual property portfolio that utilizes the most commonly used food processing techniques. As of 2017, the company’s patent portfolio includes 19 patent applications filed and pending in more than 40 countries around the world. The most recent patent applications expand Lexaria’s lipophilic food and beverage composition claims to include the processing of cannabinoids, vitamins, NSAIDs and nicotine in many of the world’s most commonly used food processing ingredients. Lexaria is expecting additional new patent awards both in the USA and internationally in 2017 and 2018.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third party partners, and has several deals signed and/or pending. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has raised more than $50 million in working capital for the companies he has led over the course of his career. He is supported by a team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.22, off by 4.69%, on 102,923 volume with 174 trades. The average volume for the last 3 months is 249,467 and the stock's 52-week low/high is $0.72/$2.54.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTCQB: ETST), via its wholly owned subsidiaries, operates in the fields of hemp cannabinoids, nutraceuticals, pharmaceuticals, medical devices and research and development. A biotechnology company, its three subsidiaries are Earth Science Pharmaceutical, Inc., Cannabis Therapeutics, Inc. and KannaBidioid, Inc. Its Canadian subsidiary is Canna Inno Laboratories, Inc. Earth Science Tech has its corporate office in Doral, Florida. Also today, NetworkNewsWire released a report on the company taking a closer look at ETST’s Hygee medical devices. To view the full article, visit: http://nnw.fm/7pEna.

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.94, off by 6.00%, on 21,038 volume with 30 trades. The average volume for the last 3 months is 115,932 and the stock's 52-week low/high is $0.421/$2.45.

Recent News

chart

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (OTC: STLHF).

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF) was highlighted today in a report by FN Media Group on how stress is mounting in the lithium sector, as producers are struggling to keep up with booming demand.

Standard Lithium Ltd. (OTC: STLHF) is focused on unlocking the value of existing large-scale U.S.-based lithium brine resources that can quickly be brought into production. The Company believes new lithium production can rapidly be brought on stream by minimizing project risks at selection stage; resource, political & geographic, and regulatory & permitting; and by leveraging advances in lithium extraction technologies and processes.

The Company’s flagship project is in southern Arkansas. The more than 180,000-acre “Smackover Project” is in the most prolific and productive brine processing region in North America. Agreements with large commercial brine operators in the region will allow Standard Lithium to utilize the extensive existing infrastructure, including brine supply and disposal pipelines, water, power and a trained workforce to fast-track project development timelines.

“Arkansas produces about 9.4 billion gallons of brine per year, according to 2010-2016 average statistics reported by the Arkansas Oil & Gas Commission.”

Standard Lithium signed a binding MoU with global specialty chemicals company LANXESS Corporation and its U.S. affiliate Great Lakes Chemical Corporation with the purpose of demonstrating the commercial viability of extraction of lithium from brine (“tail brine”) that is produced as part of LANXESS’ bromine extraction business at its three Southern Arkansas facilities.

LANXESS’ land operations in Southern Arkansas encompass more than 150,000 acres, 10,000 brine leases and surface agreements and 250 miles of pipelines. LANXESS extracts the brine from its wells located throughout the area, and the brine is transported to the three Arkansas plants through a network of pipelines. The three bromine extraction plants currently employ approximately 500 people and process and reinject several hundred thousand barrels of brine per day.

Standard Lithium has developed a breakthrough rapid lithium extraction process that reduces the recovery time of extracting lithium from brine to as little as several hours vs. the current industry method that takes years. The process is also much more environmentally friendly with a significantly smaller footprint than the conventional processes. The company has a signed agreement to locate a demonstration scale lithium extraction plant inside one of LANXESS’ chemical plants in Southern Arkansas.

The Company has also signed an option agreement with NYSE-listed Tetra Technologies for the lithium rights for exploration, extraction, and possible commercial development on approximately 30,000 acres of brine leases in Southern Arkansas. The largest available land package.

Recent laboratory results of four brine samples recovered from two existing wells in Standard Lithium’s project area showed lithium concentrations ranging between 347-461 mg/L lithium, with an average of 450 mg/L lithium in one of the wells and 350 mg/L in the other. Geological modeling of the project area is complete, and a maiden resource report is on the horizon.

Market Opportunity

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.

Leadership

Standard Lithium’s commitment to being a premier, innovation-driven company focused on developing and commercializing new modern processes for lithium extraction is bolstered by the leading experts that comprise the company’s Scientific Advisory Council. Each member was selected because of their experience and expertise in areas that are central to and/or complement Standard Lithium’s current development plans. Standard Lithium recently welcomed to the Council world-renowned chemist Dr. Barry Sharpless, the recipient of the 2001 Nobel Prize in Chemistry for his work on chirally catalyzed oxidation reactions.

Standard Lithium is led by a team of professionals with proven strong technical and project development skills. CEO Robert Mintak has a global network of industry contacts and is a pioneer in the rapidly evolving lithium space. COO and President Dr. Andy Robinson is an experienced geoscientist with 20+ years of experience and a PhD in Geochemistry from the University of Bristol, UK. Dr. Robinson has worked on a wide range of projects in the resource, power and energy sectors in Europe, Africa, and North and South America.

The company recently appointed Robert Cross as non-executive chairman. Cross is an engineer with 25 years of experience as a financier and company builder in the mining and oil and gas sectors. He co-founded and serves as chairman of B2Gold, a top-performing growing gold producer which is expected to achieve nearly 1 million ounces of low-cost gold production in 2018. He was also co-founder and chairman of Bankers Petroleum Ltd.; co-founder and chairman of Petrodorado Energy Ltd.; and until October 2007 was the non-executive chairman of Northern Orion Resources Inc. He also was previously the chairman and CEO of Yorkton Securities Inc., and a partner in investment banking with Gordon Capital Corp. in Toronto. Cross has an engineering degree from the University of Waterloo (1982) and received an MBA from Harvard in 1987.

Following a multi-million-dollar financing in Q1 2018, Standard Lithium is well-positioned to meet its upcoming milestones including two maiden resource reports and the launch of its breakthrough rapid lithium extraction technology.

Standard Lithium Ltd. (OTC: STLHF), closed the day's trading session at $0.912, off by 6.27%, on 35,050 volume with 29 trades. The average volume for the last 3 months is 52,876 and the stock's 52-week low/high is $0.604/$2.13.

Recent News

chart

Plus Products Inc. (CSE: PLUS)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS).

CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, announces publication of an article covering edible market leader Plus Products. On November 14, Plus Products Inc. (CSE: PLUS) announced that, based on Q3 2018 retail sales figures, it is the best-selling cannabis-infused edibles brand in California, the largest legal adult use cannabis market in the world. Also today, NetworkNewsWire released a report on the company detailing how Plus Products is “One to Watch.”

Plus Products Inc. (CSE: PLUS) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLUS), closed the day's trading session at $5.34, off by 8.72%, on 103,517 volume with 158 trades. The average volume for the last 3 months is 333,209 and the stock's 52-week low/high is $3.51/$7.25.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (MCOA) was pleased to announce financial results for the three and nine months ended September 30, 2018. Highlights include a 2,984 percent increase in revenues compared to the three quarters ended September 30, 2017.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0168, off by 15.58%, on 11,850,460 volume with 327 trades. The average volume for the last 3 months is 9,847,932 and the stock's 52-week low/high is $0.0166/$0.0728.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.